Ballentine Partners’s Editas Medicine EDIT Stock Holding History

Ballentine Partners’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,673	Closed	-$36.4K	–	908
2024 Q3	$36.4K	Buy	+10,673	New	+$46.5K	﹤0.01%	838

Other funds holding EDIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ballentine Partners's EDIT Position: Q4 2024 in Review

Ballentine Partners sold out of Editas Medicine (EDIT) in Q4 2024, closing a stake of 10,673 shares — an estimated $36.4K sold.

Ballentine Partners first reported a position in EDIT in Q3 2024 and held it in 1 quarter. The position peaked at $36.4K in Q3 2024. 206 funds tracked by Wall St. Rank hold EDIT as of Q4 2024.

Ballentine Partners reported no remaining Editas Medicine position as of Q4 2024 after selling out during the quarter.
Ballentine Partners sold 10,673 Editas Medicine shares in Q4 2024, an estimated $36.4K.
Ballentine Partners first reported a position in Editas Medicine in Q3 2024 and held it in 1 quarter.
Ballentine Partners's Editas Medicine position peaked at $36.4K in Q3 2024.
206 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2024.

Based on Ballentine Partners's 13F filing for Q4 2024, filed 16 Jan 2025.